Target intelligence / Profile preview

Group A streptococcal carbohydrate (GAC) (GAC)

Target
GAC
Molecular classification
Polysaccharide, Bacterial cell wall antigen, Glycoconjugate
01

Overview

Group A streptococcal carbohydrate (GAC) is the defining cell wall antigen of Streptococcus pyogenes, a major human pathogen responsible for a wide spectrum of diseases. The molecule consists of a poly-L-rhamnose backbone with N-acetylglucosamine (GlcNAc) side chains, which are essential for the structural integrity and virulence of the bacterium (Source: van Sorge et al., 2014, Cell Host & Microbe). In the context of vaccine development, GAC is formulated as a glycoconjugate by linking it to a carrier protein to induce a robust, T-cell dependent immune response (Source: Sabharwal et al., 2006, Vaccine). This target is highly conserved across nearly all Group A Streptococcus (GAS) strains, making it a superior candidate for a universal vaccine compared to the highly variable M protein (Source: Frost et al., 2023, NPJ Vaccines). The primary mechanism of action for GAC-based vaccines is the generation of opsonophagocytic antibodies that facilitate the clearance of the bacteria by the host's immune system (Source: Kastenmüller et al., 2021, Frontiers in Immunology). While GAC is a promising target, researchers must carefully evaluate the potential for cross-reactivity between the GlcNAc moiety and human tissues to ensure safety against post-streptococcal autoimmune diseases (Source: Shikhman et al., 1994, Journal of Immunology).

Other names
Group A carbohydrateLancefield Group A antigenStreptococcus pyogenes cell wall carbohydratePoly-rhamnose GlcNAc polysaccharideGAC glycoconjugate
02

Mechanism of action

Induction of protective opsonophagocytic IgG antibodies that recognize the carbohydrate epitope on the bacterial surface, leading to complement activation and phagocytosis.

03

Biological functions

Bacterial cell wall structural integrityImmune evasionAdhesion to host cellsResistance to antimicrobial peptides
04

Disease associations

Group A Streptococcal infectionPharyngitisRheumatic heart diseaseNecrotizing fasciitisToxic shock syndromeImpetigo
05

Safety considerations

Potential immunological cross-reactivity with human N-acetylglucosamine-containing tissuesTheoretical risk of exacerbating autoimmune sequelae like rheumatic feverRequirement for carrier proteins to overcome T-cell independent immune response
06

Interacting drugs

VAX-A1 (Vaxcyte)

2 more in the full profile.

07

Biomarkers

Anti-GAC IgG antibody titersOpsonophagocytic activity (OPA) index

Beyond the preview

Go deeper on Group A streptococcal carbohydrate (GAC) (GAC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Group A streptococcal carbohydrate (GAC) (GAC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call